ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Helsinn has reorganized its active pharmaceutical ingredient (API) manufacturing operations in its home country of Switzerland and in Ireland. The company will expand its advanced synthesis site in Biasca, Switzerland, after having invested in its oral-dosage-form R&D site near Dublin earlier this year. It also will sell its Helsinn Chemicals Ireland plant, in Dublin, to generic API supplier Medinco C.F.M. Group of Milan, Italy. Helsinn's focus is on the production of highly potent drug compounds.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter